ReviewFrontiers in oncology2017
Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.
Review in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05250336 (Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer), which is not on this map. Cited by 64 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer
Who cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Automated scoring methods for quantitative interpretation of Tumour infiltrating lymphocytes (TILs) in breast cancer: a systematic review.BMC cancer · 2024Pooled it
- SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Pooled it
- Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.Breast cancer research : BCR · 2022Trial
- AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.NPJ breast cancer · 2026Article
- Crowdsourcing enables robust cell annotation for breast cancer pathology.Scientific reports · 2026Article
- Comparison of programmed death-1 (PD-1)-positive T-cells with known prognostic indicators in breast cancer.Journal of family medicine and primary care · 2025Article
- Tumor Hypoxia: How Conventional Histology Is Reshaped in Breast Carcinoma.International journal of molecular sciences · 2025Review
- Automated deep learning-based assessment of tumour-infiltrating lymphocyte density determines prognosis in colorectal cancer.Journal of translational medicine · 2025Article
- Immune monitoring of neoadjuvant chemo-immunotherapy for triple-negative breast cancer.Frontiers in immunology · 2025Review
- Breaking the heterogeneity barrier: a robust prognostic signature for survival stratification and immune profiling in triple-negative breast cancer.Frontiers in immunology · 2025Article
- Prioritizing cases from a multi-institutional cohort for a dataset of pathologist annotations.Journal of pathology informatics · 2025Article
- The expression of epidermal growth factor receptor 2 and its relationship with tumor-infiltrating lymphocytes and clinical pathological features in breast cancer patients.Open life sciences · 2025Article
- AI drives the assessment of lung cancer microenvironment composition.Journal of pathology informatics · 2024Article
- Detailed Profiling of the Tumor Microenvironment in Ethnic Breast Cancer, Using Tissue Microarrays and Multiplex Immunofluorescence.International journal of molecular sciences · 2024Article
- Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade.Cancers · 2024Article
- Association of androgen receptor and tumour-infiltrating lymphocytes with bone recurrence in triple-negative breast cancer.Journal of bone oncology · 2024Article
- Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.American journal of cancer research · 2024Review
- Update on current and new potential immunotherapies in breast cancer, from bench to bedside.Frontiers in immunology · 2024Review
- Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival.Scientific reports · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interest in tumor-infiltrating lymphocytes (TILs) as a prognostic biomarker in breast cancer has grown in recent years. Biomarkers must undergo comprehensive evaluation in terms of analytical validity, clinical validity and clinical utility before they can be accepted as part of clinical practice. The International Immuno-Oncology Biomarker Working Group has developed a practice guideline on scoring TILs in breast cancer in order to standardize TIL assessment. The prognostic value of TILs as a biomarker in early-stage breast cancer has been established by assessing tumor samples in thousands of patients from large prospective clinical trials of adjuvant therapy. There is a strong linear relationship between increase in TILs and improved disease-free survival for triple-negative and HER2-positive disease. Higher levels of TILs have also been associated with increased rates of pathological complete response to neoadjuvant therapy. TILs have potential clinical utility in breast cancer in a number of areas. These include prediction of responders to immune checkpoint blockade, identification of primary HER2-positive and triple-negative patients who have excellent prognoses and may thus be appropriate for treatment de-escalation, and potentially incorporation into a neoadjuvant endpoint which may be a better surrogate maker for drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.